Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021 Year: 2021
Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Real-world effectiveness of reslizumab for severe eosinophilic asthma (SEA) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
The immunological features of the severe steroid-resistant asthma Source: Eur Respir J 2003; 22: Suppl. 45, 479s Year: 2003
COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth Source: ERJ Open Res, 6 (4) 00457-2020; 10.1183/23120541.00457-2020 Year: 2020
Special considerations in asthma Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=293 Year: 2003
Is hypereosinophilic asthma a specific phenotype of asthma? Source: Annual Congress 2011 - Phenotyping asthma: a clue for treatments? Year: 2011
Omalizumab and Churg-Strauss syndrome Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Clinical features of steroid-resistant patients with severe steroid-dependent bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 133s Year: 2004
Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019
Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma Source: Virtual Congress 2020 – How do different treatment strategies translate into costs Year: 2020
Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Exacerbations of severe asthma in patients treated with mepolizumab Source: Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018 Year: 2018
Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005
Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021